PS
KYMR icon

Principal Securities’s Kymera Therapeutics KYMR Stock Holding History

Principal Securities’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$283 – 2565
2025
Q3 		$283 Hold
5
– – ﹤0.01% 3616
2025
Q2 		$218 Buy
+5
New +$172 ﹤0.01% 3590

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Principal Securities's KYMR Position: Q4 2025 in Review

Principal Securities sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 5 shares — an estimated $283 sold.

Principal Securities first reported a position in KYMR in Q2 2025 and held it in 2 quarters. The position peaked at $283 in Q3 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Principal Securities reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 5 Kymera Therapeutics shares in Q4 2025, an estimated $283.
  • Principal Securities first reported a position in Kymera Therapeutics in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Kymera Therapeutics position peaked at $283 in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.